The Valuation Gap Is Real
European healthtech companies with documented regulatory compliance — including AI Act positioning — tend to be valued significantly higher than comparable companies without documentation.
Same technology, same market, but a meaningful valuation gap driven by regulatory status. The difference is not the AI — it is the documentation around the AI. Acquirers and growth investors price regulatory uncertainty as a liability, and they discount accordingly.
The Commission Just Unified the Pathway
The European Commission proposed integrating AI Act conformity assessment into the existing Medical Device Regulation (MDR) route. This means medical AI systems won’t face two separate certification processes. One pathway, not two.
This makes the timeline shorter — and classification documentation more urgent. Companies that assumed they had time to address AI Act compliance separately from their MDR process now face a consolidated deadline. The regulatory pathway is simpler, but the window to prepare is narrower.
Gate 02: Where Medical AI Meets the AI Act
Under Article 6(1), AI systems that are safety components of products covered by EU harmonisation legislation — including medical devices under MDR — are classified as high-risk. This triggers the full obligation set:
For medical AI, Gate 02 — Article 6(1) — is the relevant classification pathway. Your system is high-risk not because it appears in Annex III, but because it is a safety component of a product already covered by Union harmonisation legislation (MDR).
What Investors Are Asking Now
Investors in European healthtech increasingly ask “Where are you on AI Act?” before discussing ARR. This is the same shift that happened with GDPR in 2019-2020 — regulatory status became a deal qualifier, not an afterthought.
A Sprinkling Act report in your data room answers this question for €690. It maps your system article by article, identifies your classification pathway, and gives investors a dated, verifiable compliance position — before they ask.
Sources
- [1]EUR-Lex (July 12, 2024) — Regulation (EU) 2024/1689 — Artificial Intelligence Act (full text) eur-lex.europa.eu/eli
- [2]EU AI Act — Article 6 — Classification Rules for High-Risk AI Systems artificialintelligenceact.eu/article
- [3]EU AI Act — Annex III — High-Risk AI Systems Referred to in Article 6(2) artificialintelligenceact.eu/annex
- [4]
- [5]EUR-Lex (April 5, 2017) — Regulation (EU) 2017/745 — Medical Devices Regulation (MDR) eur-lex.europa.eu/eli
- [6]EU AI Act — Articles 9–15 — Requirements for High-Risk AI Systems artificialintelligenceact.eu/article
- [7]European Commission — Europe's Digital Decade: Digital Targets for 2030 digital-strategy.ec.europa.eu/en
Art. 5 prohibitions and GPAI rules apply today. Transparency follows in 105 days. The question is not when — it’s whether you’ve documented your position.
The MDR + AI Act Intersection
Medical AI systems face a unique compliance intersection. MDR Class IIa/IIb classification and AI Act high-risk classification overlap but are not identical. A system can be MDR-compliant but not AI Act-classified — creating a gap that regulators and acquirers will identify.
Gate 02 of the Sprinkling Act assessment specifically addresses this intersection. It evaluates whether your system qualifies as high-risk under Article 6(1) by virtue of its role as a safety component within an MDR-regulated product — and documents the obligations that follow.
What to Do Before Your Next Round
Document your AI Act position before entering fundraising or M&A discussions. The €690 cost of a full report is negligible compared to the valuation impact of documented vs undocumented compliance.
Investors who see a dated, article-mapped classification report assess lower regulatory risk — and price accordingly. The gap between 5x and 12x on a €2M ARR company is €14M in enterprise value. The report pays for itself before the first meeting.
Building medical AI in Europe? Get your AI Act classification documented before your next investor conversation.